Table 3.

Baseline clinical characteristics of patients with and without DNMT3A mutations

	Non-DNMT3A (n=360)	DNMT3A (n=203)	P Value
Demographics
Age (y)	61±15	65±13	<0.01
Age >60y, n(%)	213 (59.2)	137 (67.5)	0.06
Male sex, n(%)	209 (58.1)	89 (43.4)	<0.01
BMI (kg/m2)	28.7±6.9	27.2±5.8	0.01
Duration of follow-up, d,[Q1,Q3]	423,[144,1099]	483,[171,980]	0.97
Cardiovascular risks and disease history
Hypercholesterolemia, n(%)	90 (25.0)	49 (24.1)	0.45
Hypertension, n(%)	118 (32.8)	51 (25.1)	0.04
Diabetes, n(%)	43 (11.9)	15 (7.4)	0.06
Obesity, n(%)	109 (30.3)	51 (25.1)	0.11
Current/previous smoker, n(%)	133 (36.9)	82 (40.4)	0.36
≥2 CV risk factors*, n(%)	103 (28.6)	45 (22.2)	0.06
Coronary heart disease, n(%)	42 (11.7)	24 (11.8)	0.53
Atrial fibrillation/flutter, n(%)	31 (8.6)	6 (3.0)	0.01
Peripheral artery disease, n(%)	23 (6.4)	9 (4.4)	0.22
Chronic kidney disease, n(%)	14 (3.9)	4 (2.0)	0.16
Cerebrovascular disease, n(%)	25 (6.9)	11 (5.4)	0.30
DVT/pulmonary embolism, n(%)	20 (5.6)	9 (4.4)	0.36
Pre-existing CV diseases#, n(%)	89 (24.7)	41 (20.2)	0.13
Chemotherapy
With Anthracycline, n(%)	279 (77.5)	202 (99.5)	<0.01
Anthracycline dose, mg/m2,[Q1,Q3]	180,[134,276]	194,[180,340]	<0.01
Anthracycline >250mg/m2, n(%)	103 (28.6)	62 (30.5)	0.05
Outcome
Heart failure, n(%)	23 (6.4)	28 (13.8)	<0.01
Time to heart failure, d,[Q1,Q3]	414,[104,917]	401,[141,1083]	0.40
Death, n(%)	247 (68.6)	130 (64.0)	0.16
Time to death, d,[Q1,Q3]	271,[74,484]	277,[83,546]	0.64

BMI: body mass index; CV: cardiovascular; DVT: deep venous thrombosis;

^{* :}CV risk factors include obesity, hypertension, hypercholesterolemia and diabetes;

^{# :}CV diseases include coronary artery disease, atrial fibrillation/flutter, cerebrovascular disease, and peripheral artery disease